Advertisement

Digestive Diseases and Sciences

, Volume 56, Issue 2, pp 564–568 | Cite as

The Effects of Angiotensin Blocking Agents on the Progression of Liver Fibrosis in the HALT-C Trial Cohort

  • Barham K. Abu Dayyeh
  • May Yang
  • Jules L. Dienstag
  • Raymond T. Chung
Original Article

Abstract

Background

Therapies that can slow the progression of liver fibrosis in chronic liver disease are needed. Evidence suggests that the renin-angiotensin system (RAS) contributes to inflammation and fibrosis in chronic liver disease. Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties.

Aims

In this study, we evaluated the effects of continuous ACEi/ARB use for 3.5 years on histological liver fibrosis progression in the HALT-C Trial cohort.

Methods

In the HALT-C Trial, subjects with chronic hepatitis C and advanced hepatic fibrosis (Ishak stage ≥3) underwent serial liver biopsies at baseline, 1.5 years, and 3.5 years after randomization. The primary outcome was a ≥2-point increase in Ishak fibrosis score in at least one of the two serial biopsies. Sixty-six subjects were continuously taking ACEi/ARBs over the observation period, 126 were taking other antihypertensive medications, and 343 subjects took no antihypertensive medications.

Results

The three groups were similar in baseline fibrosis scores, and the two groups being treated with antihypertensives were taking a similar number of antihypertensive medications. Fibrosis progression occurred in 33.3% of the ACEi/ARB group, 32.5% of the other antihypertensive medications group, and in 25.7% of subjects taking no antihypertensive medications. No significant associations between ≥2-point increases in fibrosis scores and continuous ACEi/ARB use were apparent at either 1.5 or 3.5 years in diabetes-adjusted and unadjusted odds ratios.

Conclusions

ACEi/ARB therapy did not retard the progression of hepatic fibrosis.

Keywords

Renin–angiotensin system ACE inhibitors Angiotensin receptor blockers Liver fibrosis Hypertension Diabetes 

Abbreviations

ACEi

Angiotensin-converting enzyme inhibitors

ARBs

Angiotensin receptor blockers

HALT-C

Hepatitis C Long-term Treatment Against Cirrhosis

HSC

Stellate cells

OR

Odds ratio

RAS

Renin-angiotensin system

SVR

Sustained virologic response

Notes

Acknowledgments

This study was supported by the National Institute of Diabetes & Digestive & Kidney Diseases (contract numbers are listed below). Additional support was provided by the National Institute of Allergy and Infectious Diseases (NIAID), the National Cancer Institute, the National Center for Minority Health and Health Disparities and by General Clinical Research Center and Clinical and Translational Science Center grants from the National Center for Research Resources, National Institutes of Health (grant numbers are listed below). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Additional funding to conduct this study was supplied by Hoffmann-La Roche, Inc., through a Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health. In addition to the authors of this manuscript, the following individuals were instrumental in the planning, conduct and/or care of patients enrolled in this study at each of the participating institutions as follows: University of Massachusetts Medical Center, Worcester, MA: (Contract N01-DK-9-2326) Gyongyi Szabo, MD, Barbara F. Banner, MD, Maureen Cormier, RN, Donna Giansiracusa, RN. University of Connecticut Health Center, Farmington, CT: (Grant M01RR-06192) Herbert L. Bonkovsky, MD, Gloria Borders, RN, Michelle Kelley, RN, ANP. Saint Louis University School of Medicine, St Louis, MO: (Contract N01-DK-9-2324) Adrian M. Di Bisceglie, MD, Bruce Bacon, MD, Brent Neuschwander-Tetri, MD, Elizabeth M. Brunt, MD, Debra King, RN. Massachusetts General Hospital, Boston, MA: (Contract N01-DK-9-2319, Grant M01RR-01066; Grant 1 UL1 RR025758-01, Harvard Clinical and Translational Science Center) Andrea E. Reid, MD, Atul K. Bhan, MD, Wallis A. Molchen, David P. Lundmark. University of Colorado Denver, School of Medicine, Aurora, CO: (Contract N01-DK-9-2327, Grant M01RR-00051, Grant 1 UL1 RR 025780-01), Gregory T. Everson, MD, Thomas Trouillot, MD, Marcelo Kugelmas, MD, S. Russell Nash, MD, Jennifer DeSanto, RN, Carol McKinley, RN. University of California—Irvine, Irvine, CA: (Contract N01-DK-9-2320, Grant M01RR-00827) Timothy R. Morgan, MD, John C. Hoefs, MD, John R. Craig, MD, M. Mazen Jamal, MD, MPH, Muhammad Sheikh, MD, Choon Park, RN. University of Texas Southwestern Medical Center, Dallas, TX: (Contract N01-DK-9-2321, Grant M01RR-00633, Grant 1 UL1 RR024982-01, North and Central Texas Clinical and Translational Science Initiative) William M. Lee, MD, Thomas E. Rogers, MD, Peter F. Malet, MD, Janel Shelton, Nicole Crowder, LVN, Rivka Elbein, RN, BSN, Nancy Liston, MPH. University of Southern California, Los Angeles, CA: (Contract N01-DK-9-2325, Grant M01RR-00043) Karen L. Lindsay, MD, MMM, Sugantha Govindarajan, MD, Carol B. Jones, RN, Susan L. Milstein, RN. University of Michigan Medical Center, Ann Arbor, MI: (Contract N01-DK-9-2323, Grant M01RR-00042, Grant 1 UL1 RR024986, Michigan Center for Clinical and Health Research) Anna S. Lok, MD, Robert J. Fontana, MD, Joel K. Greenson, MD, Pamela A. Richtmyer, LPN, CCRC, R. Tess Bonham, BS. Virginia Commonwealth University Health System, Richmond, VA: (Contract N01-DK-9-2322, Grant M01RR-00065) Mitchell L. Shiffman, MD, Richard K. Sterling, MD, MSc, Melissa J. Contos, MD, A. Scott Mills, MD, Charlotte Hofmann, RN, Paula Smith, RN. Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD: Marc G. Ghany, MD, T. Jake Liang, MD, David Kleiner, MD, PhD, Yoon Park, RN, Elenita Rivera, RN, Vanessa Haynes-Williams, RN. National Institute of Diabetes and Digestive and Kidney Diseases, Division of Digestive Diseases and Nutrition, Bethesda, MD: James E. Everhart, MD, Leonard B. Seeff, MD, Patricia R. Robuck, PhD, Jay H. Hoofnagle, MD, Elizabeth C. Wright, PhD. University of Washington, Seattle, WA: (Contract N01-DK-9-2318) Chihiro Morishima, MD, David R. Gretch, MD, PhD, Minjun Chung Apodaca, BS, ASCP, Rohit Shankar, BC, ASCP, Natalia Antonov, M. Ed. New England Research Institutes, Watertown, MA: (Contract N01-DK-9-2328) Kristin K. Snow, MSc, ScD, Anne M. Stoddard, ScD, Teresa M. Curto, MSW, MPH. Armed Forces Institute of Pathology, Washington, DC: Zachary D. Goodman, MD, PhD. Data and Safety Monitoring Board Members: (Chair) Gary L. Davis, MD, Guadalupe Garcia-Tsao, MD, Michael Kutner, PhD, Stanley M. Lemon, MD, Robert P. Perrillo, MD.

Conflict of interest

Financial relationships of the authors with Hoffmann-La Roche, Inc., are as follows: R. T. Chung receives research support. Authors with no financial relationships related to this project are: B. K. Abu Dayyeh, M. Yang, and J. L. Dienstag.

References

  1. 1.
    Bataller R, Gines P, Nicolas JM, Gorbig MN, Garcia-Ramallo E, Gasull X. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149–1156.CrossRefPubMedGoogle Scholar
  2. 2.
    Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G642–G651.PubMedGoogle Scholar
  3. 3.
    Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J. Nadph oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003;112:1383–1394.PubMedGoogle Scholar
  4. 4.
    Bataller R, Sancho-Bru P, Gines P, Lora JM, Al-Garawi A, Sole M. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117–125.CrossRefPubMedGoogle Scholar
  5. 5.
    Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis. World J Gastroenterol. 2006;12:322–326.PubMedGoogle Scholar
  6. 6.
    Wei HS, Li DG, Lu HM, Zhan YT, Wang ZR, Huang X. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCL(4). World J Gastroenterol. 2000;6:540–545.PubMedGoogle Scholar
  7. 7.
    Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745–750.CrossRefPubMedGoogle Scholar
  8. 8.
    Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001;121:148–155.CrossRefPubMedGoogle Scholar
  9. 9.
    Croquet V, Moal F, Veal N, Wang J, Oberti F, Roux J. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J Hepatol. 2002;37:773–780.CrossRefPubMedGoogle Scholar
  10. 10.
    Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCL(4). Biochem Biophys Res Commun. 2003;308:177–183.CrossRefPubMedGoogle Scholar
  11. 11.
    Wei YH, Jun L, Jun L. Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCL4 in rats. Dig Dis Sci. 2004;49:1589–1594.CrossRefPubMedGoogle Scholar
  12. 12.
    Yang L, Bataller R, Dulyx J, Coffman TM, Gines P, Rippe RA. Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. J Hepatol. 2005;43:317–323.CrossRefPubMedGoogle Scholar
  13. 13.
    Terui Y, Saito T, Watanabe H, Togashi H, Kawata S, Kamada Y. Effect of angiotensin receptor antagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology. 2002;36:1022.CrossRefPubMedGoogle Scholar
  14. 14.
    Debernardi-Venon W, Martini S, Biasi F, Vizio B, Termine A, Poli G. AT1 receptor antagonist candesartan in selected cirrhotic patients: Effect on portal pressure and liver fibrosis markers. J Hepatol. 2007;46:1026–1033.CrossRefPubMedGoogle Scholar
  15. 15.
    Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology. 2004;40:1222–1225.CrossRefPubMedGoogle Scholar
  16. 16.
    Rimola A, Londono MC, Guevara G, Bruguera M, Navasa M, Forns X. Beneficial effect of angiotensin-blocking agents on graft fibrosis in hepatitis C recurrence after liver transplantation. Transplantation. 2004;78:686–691.CrossRefPubMedGoogle Scholar
  17. 17.
    Yoshiji H, Noguchi R, Fukui H. Combined effect of an ace inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C. J Gastroenterol. 2005;40:215–216.CrossRefPubMedGoogle Scholar
  18. 18.
    Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int. 2009;29:748–753.CrossRefPubMedGoogle Scholar
  19. 19.
    Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008;359:2429–2441.CrossRefPubMedGoogle Scholar
  20. 20.
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699.CrossRefPubMedGoogle Scholar
  21. 21.
    Everhart JE, Wright EC, Goodman ZD, Dienstag JL, Hoefs JC, Kleiner DE. Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51:585–594.CrossRefPubMedGoogle Scholar
  22. 22.
    Cholongitas E, Vibhakorn S, Lodato F, Burroughs AK. Angiotensin II antagonists in patients with recurrent hepatitis C virus infection after liver transplantation. Liver Int. 2010;30:334–335.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Barham K. Abu Dayyeh
    • 1
  • May Yang
    • 2
  • Jules L. Dienstag
    • 3
  • Raymond T. Chung
    • 4
  1. 1.Gastrointestinal UnitMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  2. 2.New England Research InstitutesWatertownUSA
  3. 3.Gastrointestinal UnitMassachusetts General Hospital, Harvard Medical SchoolBostonUSA
  4. 4.Gastrointestinal UnitMassachusetts General Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations